Form 4: Cytek Biosciences CEO Boosts Stake via RSU Vesting

Cytek Biosciences' President and CEO, Wenbin Jiang, increased his direct beneficial ownership of common stock through the vesting and exercise of Restricted Stock Units, with some shares withheld for tax obligations.

Summary

• Wenbin Jiang, President and CEO of Cytek Biosciences, reported multiple transactions on November 18, 2025, related to his equity holdings.
• Acquired a total of 69,641 shares of Cytek Biosciences common stock through the vesting of Restricted Stock Units (RSUs).
• Disposed of a total of 27,406 shares of common stock at a price of $5.53 per share to satisfy tax withholding obligations associated with the RSU vesting.
• Following these transactions, Mr. Jiang's direct beneficial ownership of common stock increased by a net of 42,235 shares.
• The total direct beneficial ownership of common stock after these transactions is 5,356,652 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the vesting of Restricted Stock Units and subsequent tax withholding. While shares were disposed of for taxes, there was a net increase in direct beneficial ownership, which is generally viewed as neutral to slightly positive, reflecting standard compensation practices.

Positives

• President and CEO Wenbin Jiang increased his direct beneficial ownership of Cytek Biosciences common stock by a net of 42,235 shares, which can be viewed as a positive signal of management alignment with shareholder interests.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled and non-discretionary nature.

Negatives

• A total of 27,406 shares of common stock were disposed of to cover tax withholding obligations, which reduces the immediate direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The net increase in the CEO's direct beneficial ownership, even through routine vesting, can be seen as a positive signal of continued alignment between management and shareholder interests.
• Employees: The RSU vesting demonstrates the company's executive compensation structure and the long-term incentive plans in place for key personnel.

Next Steps

• Continued quarterly vesting of RSU awards on various dates (e.g., August 18, November 18, February 18, May 18, March 10) until fully vested, as per the detailed vesting schedules for the different RSU grants.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled insider transactions related to the vesting of Restricted Stock Units and subsequent tax withholding. While the CEO's direct beneficial ownership increased on a net basis, these are not discretionary open market purchases or sales that would typically signal a strong change in sentiment. The transactions are expected and do not provide new information to warrant a change in investment recommendation.

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Transaction, CEO, Restricted Stock Units, RSU Vesting, Share Ownership, Tax Withholding, Equity Compensation